GPD1 modulators(glycerol-3-phosphate dehydrogenase 1 modulators), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases+ [5]

Active Indication

Thyroid CancerLaryngeal DiseasesLymphoid Interstitial Pneumonia+ [3]

Inactive Indication

Diabetes Mellitus, Type 2Recurrent Endometrial Cancer

Originator Organization

Elcelyx Therapeutics, Inc.

Active Organization

Alexion Pharmaceuticals, Inc.Sidney Kimmel Cancer Center at Thomas Jefferson University

Uniwersytet Medyczny w Bialymstoku

+ [2]

Inactive Organization

AstraZeneca PLC

Elcelyx Therapeutics, Inc.

Anji Pharmaceuticals, Inc.Startup

+ [1]

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC4H11N5

InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N

CAS Registry657-24-9

1,035

Clinical Trials associated with Metformin

NCT05646199 / Not yet recruitingPhase 2/3IIT

The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period.
The main question it aims to answer is:
• Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS?
Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly.
The maximum duration of participation for the patients in the trial is 32 weeks.
Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

Start Date01 Mar 2025

Sponsor / Collaborator

The University of Hull

NCT06439758 / Not yet recruitingPhase 4IIT

Effects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes

Both diabetes mellitus and osteoporosis are prevalent diseases with crucial associated mortality and morbidity. There is no clear relevance between bone diseases and diabetes mellitus. Previous research indicates that diabetes and complications related to this disease can contribute to bone disease and DM can also determine bone health. Both kinds of diabetes mellitus bring fracture risk, the most substantial clinical osteoporosis endpoint, which has crucial impact on mortality and morbidity including quality of life of an individual. Although research shows that there is association between Type 1 diabetes (T1DM) and decreased bone mineral density (BMD) values, patients with Type 2 diabetes (T2DM) have either normal or higher than expected BMD values usually. General Objective: To determine the influence of first-line anti-DM therapies in bone turnover markers and metabolism among T2DM naïve Saudi adults.
Specific objectives:
To investigate the differences in the 3- and 6-month effects of metformin alone, lifestyle intervention alone and combination (metformin + lifestyle modification) on bone markers in T2DM naïve Saudi adults.
To investigate the differences in the 3- and 6-month effects of metformin alone, lifestyle intervention alone and combination (metformin + lifestyle modification) on metabolism in T2DM naïve Saudi adults.

Start Date01 Aug 2024

Sponsor / Collaborator

King Saud University

NCT06446531 / RecruitingPhase 1IIT

Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics

The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.

Start Date01 Jul 2024

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

100 Clinical Results associated with Metformin

100 Translational Medicine associated with Metformin

100 Patents (Medical) associated with Metformin

27,510

Literatures (Medical) associated with Metformin

31 Dec 2024·Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Comparative effects of the antioxidant glutathione with metformin and Diane-35 on hormonal, metabolic, and inflammatory indicators in a DHEA-induced PCOS rat model

Article

Author: Tanoglu, Fatma Basak ; Tok, Olgu Enis ; Timur, Hikmet Tunç ; Özkara, Gülçin ; Coşar, Aslı ; Çetin, Çağlar ; Neccar, Duygu ; Özcan, Pınar

OBJECTIVE:

Comparison of hormonal, metabolic and inflammatory markers of glutathione with metformin and Diane-35 in a rat model of PCOS induced by dehydroepiandrosterone.

METHODS:

Twenty-five female rats were randomized into four groups. Group 1 was administered a subcutaneous dose of 0.2 ml saline/day. Group 2 was given 0.2 ml of 1% carboxymethyl cellulose (CMC)/day orally for 28 days. A PCOS model was established with DHEA in rats. Group 3 was given 4.5 mg/kg/day of Diane-35 orally dissolved in 1% CMC for 28 days. Group 4 was given 300 mg/kg/day of metformin orally dissolved in 1 ml of saline for 28 days, and Group 5 was administered 100 mg/kg of glutathione intraperitoneally on days 35, 42, and 49. On day 56, the rats were sacrificed. Serum markers and follicle count were examined.

RESULTS:

Serum IL-6, hs-CRP, insulin, testosterone, SHBG, and MDA values were significantly lower in the glutathione group than in the PCOS group (p = 0.0006, p = 0.023, p = 0.0082, p = 0.0007, p = 0.0048, and p < 0.0001, respectively).The number of all follicles was similar between the control and glutathione groups (p < 0.05). When we compared the other groups with the PCOS group, the number of primary, secondary, atretic, and cystic follicles was significantly lower in the metformin and glutathione groups. The number of primordial and antral follicles was significantly higher than in the PCOS group.

CONCLUSIONS:

Glutathione plays anti-inflammatory and antioxidant roles, similar to metformin, by lowering serum IL-6, insulin, testosterone, CRP, and MDA levels; decreasing atretic/cystic follicle count; and improving antral follicle count and folliculogenesis in PCOS patients.

01 Dec 2024·Molecular biology reports

Effect of zinc oxide nanocomposite and ginger extract on lipid profile, glucose, pancreatic tissue and expression of Gpx1 and Tnf-α genes in diabetic rat model

Article

Author: Yazdanpanahi, Nasrin ; Talebian, Nasrin ; Hassanpour, Shahram ; Naghsh, Nooshin

BACKGROUND:

Diabetes is a life-threatening health condition that requires expensive treatment and places a significant financial burden on society. Consequently, this study aimed to explore the potential of low and high concentrations of ginger extract, ZnO-NPs, and a combination of both to help manage diabetes and reduce high levels of lipids in diabetic rats.

METHODS AND RESULTS:

The research focused on agglomerated nanoparticles under 100 nm, specifically ZnO nanoparticles. The size of the nanoparticles was determined using X-ray diffraction analysis and scanning electron microscopy analysis, with a monodisperse particle size distribution of 20 to 48 nm and an average size of 38 nm, as shown by dynamic light scattering. Fourier transform infrared spectroscopy revealed the presence of typical peaks of ginger extract and ZnO-NPs in the nanocomposite structure. The pancreatic tissue histopathological study indicated that a concentration of 10 mg/kg of the composite had the most significant antidiabetic effect compared to other treatments. Lower concentrations could significantly reduce and balance fasting blood sugar and triglycerides levels while also increasing the high-density lipoproteins levels. However, all treatments induced a significant decrease in total cholesterol and low-density lipoproteins levels. Only metformin and ZnO-NPs in lower concentrations could decrease very low-density lipoproteins levels. The molecular technique showed that a low concentration of the composite led to the most significant decrease in Tnf-α gene expression compared to the diabetic group. The expression of the glutathione peroxidase 1 (Gpx1) gene in treated groups had no significant difference with the level of Gpx1 expression in the control rats.

CONCLUSIONS:

In general, this study demonstrated that lower concentrations of the treatments, especially composite, were more effective for treating diabetic rats due to reduced pancreatic tissue damage.

01 Sep 2024·Neural regeneration research

Metformin alleviates spinal cord injury by inhibiting nerve cell ferroptosis through upregulation of heme oxygenase-1 expression

Article

Author: Wang, Zhihua ; Zhou, Wu ; Zhang, Lulu ; Zhang, Zhixiong ; Li, Meihua

JOURNAL/nrgr/04.03/01300535-202409000-00037/figure1/v/2024-01-30T062302Z/r/image-tiff Previous studies have reported upregulation of heme oxygenase-1 in different central nervous system injury models. Heme oxygenase-1 plays a critical anti-inflammatory role and is essential for regulating cellular redox homeostasis. Metformin is a classic drug used to treat type 2 diabetes that can inhibit ferroptosis. Previous studies have shown that, when used to treat cardiovascular and digestive system diseases, metformin can also upregulate heme oxygenase-1 expression. Therefore, we hypothesized that heme oxygenase-1 plays a significant role in mediating the beneficial effects of metformin on neuronal ferroptosis after spinal cord injury. To test this, we first performed a bioinformatics analysis based on the GEO database and found that heme oxygenase-1 was upregulated in the lesion of rats with spinal cord injury. Next, we confirmed this finding in a rat model of T9 spinal cord compression injury that exhibited spinal cord nerve cell ferroptosis. Continuous intraperitoneal injection of metformin for 14 days was found to both upregulate heme oxygenase-1 expression and reduce neuronal ferroptosis in rats with spinal cord injury. Subsequently, we used a lentivirus vector to knock down heme oxygenase-1 expression in the spinal cord, and found that this significantly reduced the effect of metformin on ferroptosis after spinal cord injury. Taken together, these findings suggest that metformin inhibits neuronal ferroptosis after spinal cord injury, and that this effect is partially dependent on upregulation of heme oxygenase-1.

252

News (Medical) associated with Metformin

25 Jun 2024

·www.drugs.com

Intermittent Fasting Aids Early Diabetes Outcomes More Than Drugs

TUESDAY, June 25, 2024 -- Intermittent fasting may be a more effective intervention than drugs for people with early diabetes and either obesity or overweight, according to a study published online June 21 in JAMA Network Open . Lixin Guo, M.D., from the Chinese Academy of Medical Sciences in Beijing, and colleagues evaluated the effect of intermittent fasting (two nonconsecutive fasting days and five days of habitual intake per week and meal replacement diet (5:2 MR) on glycemic control among patients with early type 2 diabetes compared to metformin and empagliflozin for 16 weeks. Analysis included 405 individuals with overweight or obesity randomly assigned to the groups (1:1:1). The researchers found that from baseline to week 16, participants in the 5:2 MR group showed the greatest reduction in HbA1c (least-squares mean [LSM], −1.9 percent), which was significantly greater than patients receiving metformin (adjusted LSM difference, −0.3 percent) and empagliflozin (adjusted LSM difference, −0.4 percent). The mean weight loss in the 5:2 MR group (LSM, −9.7 kg) was also greater at week 16 than the metformin (LSM, −5.5 kg) and empagliflozin (LSM, −5.8 kg) groups. "The 5:2 MR approach may serve as an effective initial lifestyle intervention instead of antidiabetic drugs for patients with type 2 diabetes," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

21 Jun 2024

·www.drugs.com

Timing of Metformin Important in Metformin-Treated Type 2 Diabetes

FRIDAY, June 21, 2024 -- Glucose lowering by metformin is greater when given before enteral glucose among patients with type 2 diabetes controlled by metformin monotherapy, according to a study recently published in Diabetologia . Cong Xie, Ph.D., from the University of Adelaide in Australia, and colleagues studied 16 participants with type 2 diabetes that was relatively well controlled by metformin monotherapy on four separate days. Participants were randomly assigned on each day to receive a bolus infusion of metformin via a nasoduodenal catheter at −60, −30, or 0 minutes (saline at other time points) or saline at all time points (control) followed by an intraduodenal glucose infusion at 0 to 60 minutes. The researchers identified a treatment-by-time interaction for metformin in terms of reducing plasma glucose levels and increasing plasma glucagon-like peptide 1 (GLP-1) and insulin levels. A greater reduction in plasma glucose levels was seen when metformin was administered at −60 or −30 minutes versus 0 minutes; the increases in plasma GLP-1 were only seen when metformin was administered at −60 or −30 minutes. Metformin enhanced glucose-induced insulin secretion, although it did not influence insulin sensitivity; on the three days when metformin was given, the increases in plasma insulin levels were comparable. "Metformin is more effective in glucose-lowering when given before, rather than with, enteral glucose, and this is associated with a greater GLP-1 response," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

20 Jun 2024

·www.prnewswire.com

Polycystic Ovarian Syndrome Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight

According to DelveInsight's estimates, the increasing prevalence of diabetes, obesity, hormonal disorders, socioeconomic factors, changes in sedentary lifestyle, and growing consumption of unhealthy diets among women, is expected to fuel the polycystic ovary syndrome market. LAS VEGAS, June 20, 2024 /PRNewswire/ -- DelveInsight's Polycystic Ovarian Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, polycystic ovarian syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Polycystic Ovarian Syndrome Market Report According to DelveInsight's analysis, the market size for polycystic ovarian syndrome is expected to grow significantly by 2034. According to the data provided by the Centers for Disease Control and Prevention (CDC), PCOS is one of the most common causes of female infertility, affecting 6% to 12% of US women of reproductive age. According to the data published by NHS, PCOS is thought to be very common, affecting about 1 in every 10 women in the UK. Leading polycystic ovarian syndrome companies such as Spruce Biosciences, and others are developing novel polycystic ovarian syndrome drugs that can be available in the polycystic ovarian syndrome market in the coming years. The promising polycystic ovarian syndrome therapies in the pipeline include Tildacerfont, among others. Discover which therapies are expected to grab the major polycystic ovarian syndrome market share @ Polycystic Ovarian Syndrome Market Report Polycystic Ovarian Syndrome Overview Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women, presenting a variety of signs, symptoms, and phenotypes. These can include reproductive, endocrine, and metabolic changes. PCOS is marked by dysfunction of the hypothalamic–pituitary–ovary axis and anovulation. Unlike other ovulatory failures characterized by inadequate ovarian follicle growth or suppressed gonadotropin secretion, PCOS usually involves androgen excess and subtle changes in serum levels of gonadotropins and estrogens that routine tests may not detect. The exact cause of PCOS remains unclear, but many women with the condition exhibit insulin resistance. Elevated insulin levels can lead to increased androgen production. Obesity can also raise insulin levels, exacerbating PCOS symptoms. PCOS often runs in families. Symptoms of PCOS may include missed or irregular periods, very light periods, enlarged ovaries or those with many cysts, excessive body hair (hirsutism) on the chest, stomach, and back, weight gain, particularly around the abdomen, acne or oily skin, and infertility. Polycystic Ovarian Syndrome Epidemiology Segmentation The polycystic ovarian syndrome epidemiology section provides insights into the historical and current polycystic ovarian syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The polycystic ovarian syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Polycystic Ovarian Syndrome Diagnosed Prevalent cases of Polycystic Ovarian Syndrome Treatable Cases of Polycystic Ovarian Syndrome Polycystic Ovarian Syndrome Treatment Market The primary goal of treating polycystic ovarian syndrome is to manage symptoms and lower the risk of long-term complications. Presently, most treatments target the patient's main concern. The focus of treatment is on alleviating symptoms of hyperandrogenism, regulating menstrual cycles, and facilitating conception. Maintaining a healthy weight by following a balanced diet and engaging in regular exercise can enhance insulin sensitivity and help regulate menstrual cycles in individuals with PCOS who are overweight or obese. Incorporating complex carbohydrates, lean proteins, and plenty of vegetables into the diet can be advantageous. Some women with PCOS might find a low-carbohydrate or low-glycemic index diet particularly beneficial. Physical activity also aids in improving insulin resistance and managing weight. Spironolactone and flutamide can help decrease excess hair growth and acne by inhibiting the effects of male hormones (androgens). While Metformin is not approved for PCOS treatment in the UK, it can be prescribed "off-label" due to its benefits for many women with PCOS who have insulin resistance. Metformin can aid in improving fertility, regulating menstrual cycles, and lowering miscarriage risks. Additionally, it offers long-term health benefits like reducing high cholesterol levels and decreasing the risk of heart disease. To know more about polycystic ovarian syndrome treatment guidelines, visit @ Polycystic Ovarian Syndrome Management Polycystic Ovarian Syndrome Pipeline Therapies and Key Companies The pipeline for PCOS is bleak with only a few companies working diligently. Of all the major market players, Spruce Biosciences is developing Tildacerfont. Tildacerfont is a CRF1 receptor antagonist developed to potentially provide significantly better disease management and reduce steroid use in patients with classic congenital adrenal hyperplasia and other conditions with elevated adrenocorticotropic hormone (ACTH) levels. It works by binding to CRF1 receptors in the pituitary gland, thereby inhibiting the overproduction of ACTH and reducing the production of adrenal androgens like androstenedione, a precursor to testosterone. Tildacerfont is typically well-tolerated in both healthy individuals and those with rare endocrine disorders. Spruce is carrying out the P.O.W.E.R. study, a randomized, placebo-controlled, dose-escalation trial to assess the safety and efficacy of tildacerfont titrated to 200 mg once daily compared to a placebo over 12 weeks in subjects with PCOS and elevated adrenal androgens, measured by baseline dehydroepiandrosterone sulfate (DHEAS) levels. PCOS is a common hormonal disorder in women of reproductive age, characterized by hirsutism, irregular menstrual cycles, infertility, and ovarian cysts. If approved, Tildacerfont could be beneficial for women with a rare form of PCOS resulting from hyperresponsiveness to adrenal androgens. Discover more about polycystic ovarian syndrome drugs in development @ Polycystic Ovarian Syndrome Clinical Trials Polycystic Ovarian Syndrome Market Dynamics The dynamics of the polycystic ovarian syndrome market are expected to change in the coming years. Rising awareness about PCOS and its associated complications, such as infertility, metabolic syndrome, and diabetes, has heightened the demand for effective diagnostic and treatment options. Advances in medical technology and diagnostics have also played a significant role, with improved imaging techniques and blood tests enabling earlier and more accurate detection of PCOS. Additionally, the growing emphasis on personalized medicine and tailored treatment regimens is fueling the market, as healthcare providers seek to offer more specific and effective therapies for managing PCOS symptoms. Furthermore, potential therapies are being investigated for the treatment of polycystic ovarian syndrome, and it is safe to predict that the treatment space will significantly impact the polycystic ovarian syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the polycystic ovarian syndrome market in the 7MM. However several factors may impede the growth of the polycystic ovarian syndrome market. One of the major challenges is the lack of standardized diagnostic criteria, which can lead to underdiagnosis or misdiagnosis, thus limiting the potential market size. Treatment adherence is another concern, as the chronic nature of PCOS often requires long-term management strategies that patients may find difficult to maintain. Furthermore, there is a need for more comprehensive and effective treatment options; current therapies primarily focus on symptom management rather than addressing the underlying causes of PCOS. Moreover, polycystic ovarian syndrome treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the polycystic ovarian syndrome market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the polycystic ovarian syndrome market growth. Scope of the Polycystic Ovarian Syndrome Market Report Therapeutic Assessment: Polycystic Ovarian Syndrome current marketed and emerging therapies Polycystic Ovarian Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Polycystic Ovarian Syndrome Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Polycystic Ovarian Syndrome Market Access and Reimbursement Download the report to understand which factors are driving polycystic ovarian syndrome market trends @ Polycystic Ovarian Syndrome Market Trends Table of Contents Related Reports Polycystic Ovarian Syndrome Pipeline Polycystic Ovarian Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycystic ovarian syndrome companies, including Spruce Biosciences, Zydus Therapeutics, AbbVie, among others. Polycystic Ovarian Syndrome Epidemiology Forecast Polycystic Ovarian Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted polycystic ovarian syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Type 2 Diabetes Pipeline Type 2 Diabetes Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others. Type 2 Diabetes Market Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc. , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Drug Approval

100 Deals associated with Metformin

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10BA02	DB00331

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thyroid Cancer	Phase 3	PL	Uniwersytet Medyczny w Bialymstoku	01 Nov 2022
Diabetes Mellitus, Type 2	Phase 3	US	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	CZ	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	MX	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	PL	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	PR	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	RO	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	RU	AstraZeneca PLC	01 Sep 2012
Diabetes Mellitus, Type 2	Phase 3	GB	AstraZeneca PLC	01 Sep 2012
Laryngeal Diseases	Phase 2	US	Sidney Kimmel Cancer Center at Thomas Jefferson University	03 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2024	Not Applicable	Hormone receptor positive HER2 negative breast cancer PIK3CAmut	139	Alpelisib 300mg + Fulvestrant 500mg	uoznfpbxly(lmeuojwbmr) = ocykqwcbtu ovgqyjnpwh (ierjutetjx ) View more	Positive	24 May 2024
ASCO2024	Not Applicable	Metastatic Colorectal Carcinoma TP53 \| APC \| KRAS ... View more	-	Metformin+Chemotherapy	aokkbkxgnh(ttuekhwazt) = uyolbjbhrb dhkoxqgwcb (batwiuszhj ) View more	Positive	24 May 2024
				Metformin+ICI	aokkbkxgnh(ngazgmldwg) = upmnooempx xtwipqlpgi (pxlaoquagv ) View more
ChiCTR2000037943 (ASCO2024)	Phase 2	Metastatic Colorectal Carcinoma Second line	116	Metformin 1000mg PO twice daily	zcajlfkolf(yxthdcekcb) = tqutzniqcq ijiiinaghl (yuniqggqna ) View more	Positive	24 May 2024
ASCO2024	Not Applicable	Cytokine Release Syndrome Type 2 diabetes mellitus	237	Metformin	adgonilqui(ctjllnxhcr) = kdrakcfrpc pkcmmfyfsi (hxycygzipy ) View more	Positive	24 May 2024
				No Metformin	adgonilqui(ctjllnxhcr) = fynzaswnyd pkcmmfyfsi (hxycygzipy ) View more
KGOG & JGOG (ESGO2024)	Not Applicable	Advanced Cervical Carcinoma	197	Metformin users	kybccdodis(rikgrzcffr): HR = 0.635 (95% CI, 0.337 - 1.194), P-Value = 0.1587 View more	Negative	10 Mar 2024
				Non-metformin users
ASCO_GI2024	Not Applicable	Pancreatic Cancer	630	Metformin users	xxoamwcibv(fjdubzopaa) = aosvylxeqk bgnwxgtqxq (cvskfxvuzn ) View more	Negative	18 Jan 2024
				Non-metformin users	xxoamwcibv(fjdubzopaa) = phayvglwfi bgnwxgtqxq (cvskfxvuzn ) View more
Corporate Publications Manual	Phase 3	Diabetes Mellitus, Type 2	-	恒格列净+二甲双胍 (恒格列净5 mg联合组)	ngnjfkeljh(skxueozhio) = hxpoxgrvkn oztqddbdct (vpeexjazvm ) View more	Positive	08 Jan 2024
				恒格列净+二甲双胍 (恒格列净10 mg联合组)	ngnjfkeljh(skxueozhio) = mchefefjsi oztqddbdct (vpeexjazvm ) View more
NCT01524705 (FLAT-SUGAR, CTgov)	Phase 4	Diabetes Mellitus, Type 2	102	Insulin Glargine+Exenatide+Metformin	oiqhepncpl(ttivxzxzli) = zhvwqifurg yobvokdlsk (efmadrflhs, fvaiyzoesn - gtvsjpvulm) View more	-	29 Dec 2023
NCT04899349 (EPIK-B4, CTgov)	Phase 2	Advanced breast cancer	2	Fulvestrant+Alpelisib+Dapagliflozin+Metformin XR+Dapagliflozin + metformin XR (Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR)	jqktdzqdka(oxmlqmcoyk) = wpersdxiby shjpybiaxz (ynnnbaoesr, caguzclvgy - ntutyhyztb) View more	-	12 Dec 2023
				Fulvestrant+Alpelisib+Metformin XR (Alpelisib + Fulvestrant + Metformin XR)	mluebbreoe(ikotipgjyy) = ncofojfxwv laatrccarn (fwgkuphobx, wsrmrdqpds - egnuyayjzg) View more
SABCS2023	Not Applicable	Metastatic breast cancer	252	Metformin 850-1000mg twice daily	gjydmaakbe(minxhnmsdx) = pydmfyhwpf xgmikmyrqp (wpgflhrgcw )	-	05 Dec 2023
				Chemotherapy-based systemic therapy	gjydmaakbe(minxhnmsdx) = eyqhhmfkps xgmikmyrqp (wpgflhrgcw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis